High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
21.03M
+19.18%
-0.175
-23.91%
21.93M
+18.43%
-0.157
-37.33%
23.74M
+17.55%
-0.143
-34.85%
Estimates Revision
The market is revising Downward the revenue expectations for TELA Bio, Inc. (TELA) for FY2025, with the revenue forecasts being adjusted by -2.92% over the past three months. During the same period, the stock price has changed by -28.30%.
Revenue Estimates for FY2025
Revise Downward
-2.92%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.71%
In Past 3 Month
Stock Price
Go Down
-28.30%
In Past 3 Month
4 Analyst Rating
Wall Street analysts forecast TELA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELA is 4.06 USD with a low forecast of 1.25 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.140
Low
1.25
Averages
4.06
High
6.00
Current: 1.140
Low
1.25
Averages
4.06
High
6.00
Canaccord
Buy
downgrade
$7 -> $4
2025-11-18
Reason
Canaccord
Price Target
$7 -> $4
2025-11-18
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Tela Bio (TELA) to $4 from $7 and keeps a Buy rating on the shares. The firm said they posted a challenged Q3 as it missed top-line expectations and lowered full-year guidance, though it reiterated confidence in its commercial strategy and sales force structure as recent hires Jeffrey Blizzard and Jim Hagen from Abiomed (ABMD) become increasingly important pieces to the Tela Bio story.
Citizens JMP
Outperform
to
NULL
downgrade
$7 -> $5
2025-11-14
Reason
Citizens JMP
Price Target
$7 -> $5
2025-11-14
downgrade
Outperform
to
NULL
Reason
Citizens JMP lowered the firm's price target on Tela Bio to $5 from $7 and keeps an Outperform rating on the shares. Quarterly sales were shy of the Street by about 5%, reflecting several meaningful highlights, such as strong international sales and the addition of new customers, the analyst tells investors in a research note. The cons outweighed the pros, and management lowered its top-line guidance by 9% year over year, the firm adds.
Piper Sandler
Matt O'Brien
Neutral
downgrade
$2
2025-11-14
Reason
Piper Sandler
Matt O'Brien
Price Target
$2
2025-11-14
downgrade
Neutral
Reason
Piper Sandler analyst Matt O'Brien lowered the firm's price target on Tela Bio to $1.25 from $2 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 results which missed its estimate on the top-line and on the operating loss side of things. Revenue guidance for the year was lowered, which is certainly a disappointing update, Piper adds.
Canaccord Genuity
Caitlin Cronin
Strong Buy
Maintains
$12 → $7
2025-03-21
Reason
Canaccord Genuity
Caitlin Cronin
Price Target
$12 → $7
2025-03-21
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on Tela Bio to $7 from $12 and keeps a Buy rating on the shares. The firm said they posted a tough quarter significantly below consensus revenues as it lost a number of sales reps to competitors in the Q4 with the sales org already lean post commercial streamlining in the Q3. While the Q4 was a challenging one, the management team are experienced MedTech operators, and Canaccord believes they would need to see sustained sales org churn before becoming materially less constructive.
Piper Sandler
Matt O'Brien
Buy
to
Hold
Downgrades
$5 → $2
2025-03-21
Reason
Piper Sandler
Matt O'Brien
Price Target
$5 → $2
2025-03-21
Downgrades
Buy
to
Hold
Reason
Citizens Capital Markets
David Turkaly
Buy
Maintains
$12 → $7
2025-03-21
Reason
Citizens Capital Markets
David Turkaly
Price Target
$12 → $7
2025-03-21
Maintains
Buy
Reason
Citizens JMP lowered the firm's price target on Tela Bio to $7 from $12 and keeps an Outperform rating on the shares. Sales in the quarter were impacted by several factors, including competitive rep poaching by smaller wound care companies offering significant comp benefits including guaranteed contracts, the analyst tells investors in a research note. The firm still believes that Tela's two main biologic product platforms provide significant benefits to all constituents and that the premium growth profile here should be sustainable.
See All Ratings
Valuation Metrics
The current forward P/E ratio for TELA Bio Inc (TELA.O) is -1.82, compared to its 5-year average forward P/E of -4.43. For a more detailed relative valuation and DCF analysis to assess TELA Bio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.43
Current PE
-1.82
Overvalued PE
-2.73
Undervalued PE
-6.13
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-5.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.28
Undervalued EV/EBITDA
-7.68
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3.00
Current PS
0.00
Overvalued PS
4.99
Undervalued PS
1.01
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
TELA News & Events
Events Timeline
(ET)
2025-12-01
08:50:00
Lake Street Lowers Tela Bio Price Target to $3 Amid Q3 Results Shortfall
2025-11-13 (ET)
2025-11-13
16:12:31
Tela Bio projects at least a 16% increase in FY25 revenue.
2025-11-13
16:11:53
Tela Bio announces Q3 earnings per share of 19 cents, below consensus estimate of 20 cents.
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/78ea05d1b058fc899fbce21d5062b79cd3e19e49e27f756af6a1032335ee4962.png)
Preview
4.0
11-18BenzingaAlphabet Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Tuesday
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
4.0
11-18BenzingaCanaccord Genuity Keeps Buy Rating on TELA Bio, Reduces Price Target to $4
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/aee8d78e6ebb1058d9ad1212dfb1e98932461cfc7730f15c31c40e4412037b1f.jpg)
Preview
2.0
11-18NASDAQ.COMNOTV and APLT Top After-Hours Biotech Gains; ALMS, TELA, CORT, and BRTX Also Show Progress
Sign Up For More News
People Also Watch
FAQ
What is TELA Bio Inc (TELA) stock price today?
What is TELA Bio Inc (TELA)'s business?
What is the price predicton of TELA Stock?
What is TELA Bio Inc (TELA)'s revenue for the last quarter?
What is TELA Bio Inc (TELA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for TELA Bio Inc (TELA)'s fundamentals?
How many employees does TELA Bio Inc (TELA). have?